Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma.
efficacy
high risk
multiple myeloma (MM)
overall survival (OS)
pharmacokinetics
progression-free survival (PFS)
response rate
standard risk
treosulfan
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 May 2023
10 May 2023
Historique:
received:
15
03
2023
revised:
07
05
2023
accepted:
09
05
2023
medline:
22
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
(1) Background: Upfront treatment consolidation with high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) has relevantly contributed to achieving durable remissions following induction treatment in multiple myeloma (MM) patients. The optimization of HDCT regimens can, therefore, essentially contribute to improving the depth and duration of tumor remissions. To date, melphalan at 200 mg/m
Identifiants
pubmed: 37345036
pii: cancers15102699
doi: 10.3390/cancers15102699
pmc: PMC10216371
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Blood. 2022 May 5;139(18):2747-2757
pubmed: 35511184
JAMA. 1969 Jun 2;208(9):1680-5
pubmed: 5818682
Transplant Cell Ther. 2022 Sep;28(9):572-580
pubmed: 35750284
Leuk Lymphoma. 2017 May;58(5):1076-1083
pubmed: 27736269
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
Lancet Haematol. 2016 Nov;3(11):e526-e536
pubmed: 27746112
Blood Cancer J. 2022 May 30;12(5):83
pubmed: 35637223
N Engl J Med. 2022 Jul 14;387(2):132-147
pubmed: 35660812
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
N Engl J Med. 2003 May 8;348(19):1875-83
pubmed: 12736280
J Clin Med. 2021 Apr 23;10(9):
pubmed: 33922721
N Engl J Med. 1996 Jul 11;335(2):91-7
pubmed: 8649495
Bone Marrow Transplant. 2022 Jun;57(6):990-997
pubmed: 35444232
Clin Pharmacokinet. 2018 Oct;57(10):1255-1265
pubmed: 29557088
Blood. 2008 Apr 15;111(8):4039-47
pubmed: 18268097
Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):667-675
pubmed: 34059488
Bone Marrow Transplant. 2014 Jun;49(6):761-6
pubmed: 24662419
Clin Cancer Res. 2000 Nov;6(11):4209-16
pubmed: 11106234
Br J Haematol. 2022 Mar;196(6):e67-e70
pubmed: 34961917
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
Front Oncol. 2021 Sep 10;11:731478
pubmed: 34568066
Blood Cancer J. 2021 Apr 29;11(4):83
pubmed: 33927196
Bone Marrow Transplant. 2019 Dec;54(12):1923-1925
pubmed: 30890768
J Clin Oncol. 2022 Jul 20;40(21):2307-2320
pubmed: 35427190
Lancet Haematol. 2019 May;6(5):e266-e275
pubmed: 30910541
Clin Pharmacokinet. 2009;48(3):143-57
pubmed: 19385708
Int J Hematol. 2021 Feb;113(2):279-284
pubmed: 32864713
Cancers (Basel). 2022 Feb 17;14(4):
pubmed: 35205772
BMC Cancer. 2017 Feb 22;17(1):151
pubmed: 28228122
Int J Hematol. 2022 Jun;115(6):762-777
pubmed: 35534749
Br J Haematol. 2017 Dec;179(5):772-780
pubmed: 29048102
JAMA. 2022 Feb 01;327(5):464-477
pubmed: 35103762
Br J Haematol. 2020 Jun;189(5):e213-e217
pubmed: 32301111
Biol Blood Marrow Transplant. 2019 Feb;25(2):239-247
pubmed: 30244101